Investigational drug · Phase 2
BMS-986458
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed/Refractory Non-Hodgkin Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "BMS-986458"
First trial start
2023
Dec 29, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMS-986458", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed/Refractory Non-Hodgkin Lymphoma
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "BMS-986458" as an intervention, largest first.
- A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06090539 · 460 participants (planned) · Start Dec 29, 2023 · Primary completion Oct 28, 2027
Drug: BMS-986458; Rituximab and 4 more · For: Relapsed/Refractory Non-Hodgkin Lymphoma
Sites: Phoenix, Arizona; Duarte, California; Jacksonville, Florida · 76 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin Lymphoma.
Mortensen DS, Shunatona HP, Holmberg-Douglas N, et al. · J Med Chem 2026
Also in development for Relapsed/Refractory Non-Hodgkin Lymphoma
- CC-99282BMS-986369, GolcadomidePhase 37 trials
Bristol Myers Squibb · Lymphoma, Follicular, Large B-cell Lymphoma, Non-Hodgkin Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.